© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
AIDS Reader
Articles
Gastrointestinal Malignancies in HIV/AIDS
June 02, 2008
Kaposi sarcoma (KS), AIDS-related non-Hodgkin lymphoma (AIDS-NHL), and anal squamous cell carcinoma/anal intraepithelial neoplasia (SCC/AIN) are malignancies that commonly involve the GI tract in patients who have HIV/AIDS.1 Oncogenic viruses have been implicated in the etiology of each of these neoplasms-specifically, human herpes virus 8 (HHV8) in KS, Epstein-Barr virus (EBV) in AIDS-NHL, and human papillomavirus in SCC/AIN.
Acute Retroviral Syndrome: A Challenge for Primary Care
June 02, 2008
Primary HIV infection refers to the earliest stages of infection, or the interval from initial infection to seroconversion (when antibody to HIV is detectable). During this stage, many patients have symptoms of acute HIV seroconversion illness, are viremic with very high HIV RNA levels, and have negative or indeterminate findings on HIV antibody tests.
UN Sees Progress Inadequate on Children and AIDS, Los Alamos Lab Suggests HIV Spreads Faster Than Thought, Regular Laboratory Testing May Not Be Needed During Antiretroviral Therapy
June 02, 2008
UNICEF has reported that there have been some improvements for children facing AIDS, but progress is still far short of goals set for 2010 (Worsnip P. Reuters. April 3, 2008).
Treating HIV: When to Start, Who Should Treat, and Still Missing Many
June 02, 2008
Apart from clinical trials that provide highly active antiretroviral therapy shortly after the recognition of an acute seroconversion reaction-an intervention that some believe could be a prelude to eradicating HIV -there has long been debate over the optimal time to initiate antiretroviral therapy.
How Specialized Should We Be?
May 02, 2008
In the early years of the HIV/AIDS epidemic, the physicians and nurses who provided care to patients with this puzzling and clearly complex infection identified the benefits of specialized knowledge of the virus and management of the symptoms associated with its attack on the immune system.
Microbicide Group to Test Merck Drug as Vaginal Gel; FDA Alerts Doctors to Prezista’s Possible Link to Liver Damage; FDA Reviewing Safety of Ziagen and Videx
May 02, 2008
“It’s a completely different mechanism of action to what we have currently under development and what the field has under development,” said Dr Zeda Rosenberg, IPM’s CEO. “It’s pretty early in the life cycle for HIV. Most of us feel that for a microbicide to be really effective, it has to get at the infection in its earliest time points.”
Update on Antiretroviral Therapy: The 15th CROI
May 02, 2008
The 15th Conference on Retroviruses and Opportunistic Infections (15th CROI) was held in Boston from February 3 to 6, 2008. There were more than 1000 oral and poster presentations at this conference and, as is usually the case, some were quite important.
Serious Infection From Staphylococcus aureus in 2 HIV-Infected Patients Receiving Fusion Inhibitor Therapy
May 02, 2008
Fusion inhibitors are novel antiretroviral agents, administered as subcutaneous injections, approved for use in treatment-experienced HIV-infected patients.
Impact of Lipoatrophy on Patient-Reported Outcomes in Antiretroviral-Experienced Patients
May 02, 2008
Lipoatrophy is a noteworthy adverse effect of antiretroviral therapy. A 2-part literature review was conducted to assess the impact of lipoatrophy in HIV-infected persons: the first reviewed the qualitative studies that reported lipoatrophy data, and the second reviewed the clinical studies that recorded patient-reported outcome end points.
Editorial Comment: The Head Bone Is Connected to the Body Bone
May 02, 2008
Lipoatrophy is an important problem that emerged in 1998 with seminal findings reported by Carr and colleagues.1